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LONG TERM TREATMENT OF LEPROSY WITH CORTISONE*
E. C. DEL POZO, M.D., A. GONZALEZ-OCHOA, M.D., S. RICO VENEGAS, M.D.,f
M. MARTTNEZ-BAEZ, M.D. AND M. ALCARAZ, M.D.
The suppression of lepra reaction by cortisone (del Pozo and Gonzlez Ochoa,
1952) as an immediate and striking effect, opened several questions in relation
to the evaluation of cortisone as a therapeutic agent in lepra patients. Two
problems had to be solved before the systematic use of cortisone could be
advised in the clinical management of patients with the acute reaction. First,
if cortisone itself could be noxious to the natural course of the disease; second,
if the suppression of the lepra reaction could be considered unfavorable from
the standpoint of the individual's resistance to infection. Many other collateral
problems were left unsolved in the preliminary trials of this steroid in leprosy,
(for instance, a possible reduction in the initial benefit produced by the first
doses, the secondary physiological effects of cortisone, and an interference with
the therapeutic properties of the anti-leprosy drugs, etc.)
A long assay of cortisone in lepra patients was required. The present report
refers to the treatment of a group of lepromatous patients continuously treated
with cortisone during a period of one year.
MATERIAL AND METHODS
Nine patients were selected from the "Sanatorio Pedro Lopez" the Mexican
leprosarium located at Zoquiapan, State of Mexico. They were 6 cases of the
nodular variety and 3 of the diffuse form. In all of them, a lepra reaction had
been present continuously or very frequently, which made the usual treatment
with 4-4-diamine-diphenyl-sulfone impossible. This drug had produced in every
case a marked exacerbation of the reaction which forced the interruption of
such a treatment.
The following laboratory and clinical tests were performed at the beginning
and at the end of one year of observation: blood-sedimentation rate, red and
white cell counts and differentials, hemoglobin, glucose, urea, sodium, potassium,
protein and nonprotein nitrogen blood content, reagin quantification in serum
cephalin-cholesterol and thymol tests, nasal and cutaneous bacterioscopic tests,
lepromine reaction and histopathologic studies. The blood counts, blood
chemistry and histopathologic examinations were carried out several times
during the period of observation.
Cortisone acetate (Cortone, Merck) was administered orally in the niinimurn
amount necessary for a liminal suppression of the lepra reaction. This condition
was obtained with variable doses of cortisone according to the intensity of the
reaction and the individual resistance to treatment. From 25 to 175 mg. a day
* Instituto de Salubridad y Enfermedades Tropicales, Mexico, D. F.
t Sanatorio "Pedro Lopez," Zoquiapan, Mexico.
1 "Cortone" was kindly supplied by Merck and Co., Rahway, N. J., U. S. A.
Received for publication July 28, 1954.
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was required for this effect. However, the higher doses were used only for the
initial suppression of the acute phenomena, the maintenance dose being usually
smaller.
4-4-diamine-diphenyl-sulfone was given in the amount of 100 to 300 mg. a
day during part of the period of observation, with the exception of one case
(No. 9) in which it was administered during the entire one year period. This
treatment, which was always well tolerated when the patients were under
cortisone, was interrupted in most cases in order to study the independent
action of cortisone—the chief interest of this investigation.
RESULTS
Of the nodular cases, 3 were suspended in the fourth, sixth and seventh
months respectively because of lack of cooperation; one more was eliminated in
the third month due to renal complications. The clinical history of this last
patient showed that these functional disturbances had occurred before treatment.
The other two cases were treated with cortisone continuously for one year.
Of the second group, that of diffuse lepromatosis, one patient was eliminated
in the fifth month because of psychoneurotic changes which the past history of
this patient showed had been present—with long remissions—as long as two
years before treatment.
Table No. 1 indicates the form of treatment and results for each of the patients.
Lepra reaction: The prolonged administration of cortisone was shown to be
capable of bringing about a total suppression of the lepra reaction in every case,
both when this reaction resulted from DDS treatment and when it was a
spontaneous reaction. This suppression of the L.R. was obtained with variable
doses of cortisone differing in each case with the actual intensity of the reaction.
There was no evidence of habituation to cortisone during the long period of
its administration. The minimal dose of cortisone necessary to maintain the
patients without a L.R. varied from one case to the other and was between 25
mg. to 100 mg. a day for the patients without DDS and between 37.5 mg. to
150 mg. for those who received simultaneously such sulfone.
The manifestations of the L.R. in its two clinical forms of erythema nodosum
and erythema multiforme (necrosis, plaques, nodules, arthralgias, fever, neuritis,
high sedimentation rate, leukocytosis, etc.) disappeared with cortisone. Two
typical cases are described:
Case No. 8: C. R. 14 years old, L. 3* Before treatment: erythema polymorphum with
multiple abscesses which had caused ulcerations of 4 to 30 mm. in diameter, predominating
on the face, external surfaces of the superior and inferior extremities mainly over pre-
existent nodules; high fever; arthralgias; infiltrations; intense neuritis. General condition:
very poor. Leukocytes: 18,000; sedimentation rate: 95 mm. in one hour. No DDS was ad-
ministered since with each attempt, the described manifestations got considerably worse.
After two days of administration of 50 mg. of cortisone and two more days with 12.5 mg.,
all manifestations of the L.R. disappeared; temperature returned to normal, arthralgias
subsided and so did the neuritis and infiltrations. The ulcerations improved and the general
condition of the patient got considerably better. The white cell count fell to 8000 after 11
* See Foot Note in Table 1.
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days, and the sedimentation rate to 45 mm. in one hour. Once the L.R. disappeared, the
administration of DDS was possible on the ninth day after the initiation of the cortisone
treatment; the dose of DDS was 100 mg. in 24 hours. No L.R. occurred again since this
was avoided by slightly increasing the cortisone dose to 50 mg. and exceptionally to 75 ing.
It was possible to maintain the suppression of the L.R. during the 12 months of observa-
tion. Slight variations of the dose of cortisone were required; the average dose for the whole
period was 37.5 mg. a day. Sulfonic treatment was continued only during the first two
months. At the end of one year, cortisone was gradually withdrawn. However, a marked
L.R. did not reappear.
Three weeks after the end of the treatment, there occurred a relapse with small bullae
of three days' duration which regressed spontaneously.
Case No. 1. F. F. 40 years old. L.D. 1*. Before treatment numerous nodules (erythema
nodosum) and large fibrotic hyperpigmented plaques up to 15 cm. were present mainly on
arms and thighs. Sedimentation rate: 47 mm. in one hour; leukocytes: 15,600. Administra-
tion of DDS had been impossible due to the marked exacerbation of L.R. Two days after
the administration of 100 mg. of cortisone, the acute reactive phenomena disappeared.
This suppression was maintained with an average dose of 100 mg. a day. Leukocytes fell
to 7900 and the sedimentation rate to 45 mm. in one hour. DDS was administered without
the appearance of Lit. Two months later, when the patient was under DDS treatment,
cortisone was suspended. This suspension caused a reactive state of great intensity: large
plaques of erythema multiform appeared and many of them evolved to necrosis; tempera-
ture: 41 C.; arthritis with hydrarthrosis in large and small joints, vomitus and diarrhea.
The resumption of treatment with 100 to 150 mg. of cortisone produced a complete
remission of all reaction symptoms at the end of one week. After one year, cortisone was
gradually withdrawn. L.R. reappeared three weeks later with a similar intensity as before
treatment.
Natural Course of the Disease. The evolution of the lepromatous infection was
not damaged by the administration of cortisone since no new manifestations of
the disease appeared; on the contrary, in all cases an improvement in the general
condition of the patient was observed. A good example of this effect was evident
in case 8. This patient received DDS only during the first two months but the
clinical improvement of the lepromatosis was maintained during the whole year
of cortisone administration: the large and multiple nodules which had not been
modified by DDS began to be absorbed after 4 months of cortisone and a
complete disappearance was finally observed. Keloid scars, remnants from
necrosis and reactive elements became softened and flattened. Infiltration was
decreased 75 %.
L.R. in relation to the natural course of the disease, The suppression of the L.R.
obtained with cortisone did not damage the evolution of the lepromatous
infection itself. A close evaluation of all cases made this conclusion evident.
There was no evidence of a decrease in the initially observed benefit obtained
from the first doses of cortisone. In the four cases in which a year of treatment
was carried out, no higher doses of the steroid were required.
In spite of the continuous administration of cortisone for one year in doses
between 25 mg. and 100 mg. as average, no secondary physiological effects of
cortisone were observed.
No evidence of interference with the therapeutic properties of DDS was
* See Foot Note in Table 1.
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found. In those patients who received DDS treatment plus cortisone, the known
action of DDS was not altered.
Two out of the four cases in which cortisone was given for a period of one
year have remained without lepra reaction 6 months after the hormone was
withdrawn, despite the fact that DDS treatment has been resumed.
Pathology. A brief description of the microscopic findings in each case appears
in Table 1. Evidence of favorable evolution of lepromatosis was present in
several cases: the number and volume of the granulomatous formations were
reduced and the bacilli were less abundant and showed morphologic and tinctorial
changes. No peculiar pathologic alterations which could be attributed directly
to a cortisone effect were found. A detailed description of the histopathologie
study wifi be published elsewhere by one of us (M. M. B.).
DISCUSSION
The favorable effects of cortisone in the treatment of lepra patients surpassed
our expectations. The improvement of the course of the patients was not limited
to the effect of cortisone permitting the treatment with DDS. Benefit was also
evident in cases in which DDS was not given.
The benefit obtained when cortisone and DDS were used during the whole
treatment was not greater than that observed when DDS was administered
for only a short initial period. However, the small number of cases studied and
the relatively short period of one year observation do not permit a definite
conclusion of this aspect.
However, on a theoretical basis it is to be expected that the well known
favorable effect of DDS treatment, made possible by the suppression of L.R.
with cortisone, should be added to the independent action of this hormone.
The mechanism of the favorable effect of cortisone on leprosy remains to be
elucidated. A possible action on the granulomatous lesions allowing a more
effective organic defense or a direct action on these defenses themselves, are not
unlikely possibilities.
Another reasonable explanation, which cannot be overlooked, is the favorable
effect of the suppression of the lepra reaction. This hypothesis is not less founded
than the sometimes accepted theory of the beneficial significance of such a
reaction (2). In fact, no evidence has been presented, to our knowledge, that
intense reactions which commonly leave irreversible damage could be favorable
from the standpoint of infection. All available data point in the opposite direc-
tion: nerve degeneration, visceral and muco-cutaneous necrosis, ankylosis,
vascular disturbances, etc. could not be considered favorable responses unless
viewed with prejudice and old misconceptions.
The complete suppression of lepra reaction for a period of one year in our
cases by the action of cortisone is a previously unknown observation in patients
presenting this kind of reaction. In fact, the selected group of cases included in
this series, were of a continuous reactional lepromatous type, and the radical
change to non-reactional patients would appear to be the key factor in the
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explanation of the favorable results produced by cortisone, independent of any
other action of the hormone.
The prolonged use of cortisone in the doses employed in this study is not
noxious for the lepra infection as judged by all the clinical and laboratory tests
performed in this trial. This is an important conclusion because it gives an answer
to the cautious note that we were forced to include in our preliminary report
with regard to a possible noxious effect of cortisone in leprosy similar to that
described in tuberculosis.
A final pertinent comment is the lack of collateral undesirable physiological
action of the hormone in these long-treated lepra patients, and also the persistence
of the therapeutic value of the doses of cortisone initially used, after one year
of its continuous administration.
A discussion of the individual changes on reagins and other laboratory findings
would be purely speculative due to the meager evidence available.
SUMMARY
Intensive chronic lepra reaction was suppressed by cortisone during a maxi-
mum period of one year in nine patients. Favorable results on lepra evolution
were observed: resorption of diffusely inifitrated lesions, of fibrotic nodules and
of keloid scars. DDS treatment, intolerable before cortisone, was possible when
this hormone was given.
Secondary undesirable effects of cortisone did not appear.
Two cases remained without lepra reaction six months after cortisone was
withdrawn despite the fact that DDS treatment was resumed.
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